Dimethyl Fumarate Patent Expiration
Dimethyl Fumarate is Used for treating autoimmune diseases such as multiple sclerosis and relapsing forms before and after administering an inactive vaccine. It was first introduced by Biogen Inc
Dimethyl Fumarate Patents
Given below is the list of patents protecting Dimethyl Fumarate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Tecfidera | US10959972 | Methods of treating multiple sclerosis | Nov 16, 2035 | Biogen Inc |
| Tecfidera | US11007166 | Methods of treating multiple sclerosis | Nov 16, 2035 | Biogen Inc |
| Tecfidera | US11007167 | Methods of treating multiple sclerosis | Nov 16, 2035 | Biogen Inc |
| Tecfidera | US11129806 | Methods of treating multiple sclerosis | Nov 16, 2035 | Biogen Inc |
| Tecfidera | US11246850 | Methods of treating multiple sclerosis | Nov 16, 2035 | Biogen Inc |
| Tecfidera | US10391160 | Dimethyl fumarate and vaccination regimens | Mar 13, 2035 | Biogen Inc |
| Tecfidera | US10555993 | Dimethyl fumarate and vaccination regimens | Mar 13, 2035 | Biogen Inc |
| Tecfidera | US10994003 | Dimethyl fumarate and vaccination regimens | Mar 13, 2035 | Biogen Inc |
| Tecfidera | US8399514 | Treatment for multiple sclerosis | Feb 07, 2028 | Biogen Inc |
| Tecfidera | US7320999 | Dimethyl fumarate for the treatment of multiple sclerosis |
May 18, 2020
(Expired) | Biogen Inc |
| Tecfidera | US6509376 | Utilization of dialkyfumarates |
Oct 29, 2019
(Expired) | Biogen Inc |
| Tecfidera | US8759393 | Utilization of dialkylfumarates |
Jul 04, 2018
(Expired) | Biogen Inc |
| Tecfidera | US7619001 | Utilization of dialkylfumarates |
Apr 01, 2018
(Expired) | Biogen Inc |
| Tecfidera | US7803840 | Utilization of dialkylfumarates |
Apr 01, 2018
(Expired) | Biogen Inc |
| Tecfidera | US8524773 | Utilization of dialkylfumarates |
Apr 01, 2018
(Expired) | Biogen Inc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Dimethyl Fumarate's patents.
Latest Legal Activities on Dimethyl Fumarate's Patents
Given below is the list recent legal activities going on the following patents of Dimethyl Fumarate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical
| 18 Mar, 2024 | US10555993 |
| Maintenance Fee Reminder Mailed Critical
| 02 Oct, 2023 | US10555993 |
| Termination or Final Written Decision | 03 Feb, 2023 | US8399514 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Jan, 2023 | US10391160 |
| Expire Patent Critical
| 31 Oct, 2022 | US7803840 |
| Expire Patent Critical
| 01 Aug, 2022 | US8759393 |
| Maintenance Fee Reminder Mailed Critical
| 16 May, 2022 | US7803840 |
| Patent Issue Date Used in PTA Calculation Critical
| 15 Feb, 2022 | US11246850 |
| Recordation of Patent Grant Mailed Critical
| 15 Feb, 2022 | US11246850 |
| Maintenance Fee Reminder Mailed Critical
| 14 Feb, 2022 | US8759393 |
Dimethyl Fumarate's Family Patents
